Skip to main content
OpenTrials

Clinical trial condition

Histiocytic Disorders, Malignant

Explore clinical trials studying Histiocytic Disorders, Malignant. Study availability and eligibility vary by location and protocol.

271 public trials 44 recruiting studies
Refine in advanced search Browse all conditions

Histiocytic Disorders, Malignant trial results

Active, not recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
Locations
  • Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
  • UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
  • Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
  • University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
View Trial Details
Active, not recruiting

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

NCT06014762

Conditions
DLBCL, DLBCL - Diffuse Large B Cell Lymphoma, DLBCL Arising From Follicular Lymphoma, +21 more
Locations
  • Loma Linda University Cancer Center Loma Linda, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • Advent Health Orlando Orlando, Florida, United States
  • Indiana University Indianapolis, Indiana, United States
View all 16 locations
View Trial Details
Active, not recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

NCT05020678

Conditions
Aggressive Lymphoma, B-cell Acute Lymphoblastic Leukemia, Blood Protein Disorders, +43 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • The Cleveland Clinic Foundation Cleveland, Ohio, United States
  • Institute of Haematology, Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • St. Vincent's Hospital Sydney, New South Wales, Australia
View Trial Details
Active, not recruiting

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

NCT06325748

Conditions
AML/MDS, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, +33 more
Locations
  • UCLA Medical Center Los Angeles, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • TriStar Bone Marrow Transplant Nashville, Tennessee, United States
View Trial Details
Active, not recruiting

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

NCT05563844

Conditions
Dendritic Cell Sarcoma, Interdigitating, Diffuse Large B Cell Lymphoma，DLBCL, Hemic and Lymphatic Diseases, +5 more
Locations
  • Ruijin Hospital of Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai Municipality, China
  • West China Hospital of Sichuan University Chengdu, Sichuan, China
View Trial Details

Related conditions